A Prospective, Non-interventional Study of the Effectiveness, Safety, and Health Related Outcomes in Patients With Moderate to Severe Active Rheumatoid Arthritis Receiving Filgotinib
Latest Information Update: 21 May 2024
At a glance
- Drugs Filgotinib (Primary)
- Indications Rheumatoid arthritis
- Focus Therapeutic Use
- Acronyms FILOSOPHY
- Sponsors Galapagos NV
- 14 May 2024 Status changed from recruiting to active, no longer recruiting.
- 15 Nov 2023 Interim Results (n=798, as of Jan 31, 2023) assessing patient-reported outcomes such as pain, fatigue and work productivity, which are negatively impacted by RA, presented at the ACR Convergence 2023.
- 03 Jun 2023 Interim results (n=480) assessing baseline characteristics and up to 6-month safety data from the first 480 pts treated with FIL in the FILOSOPHY study (NCT04871919), and in two mutually exclusive subgroups based on age and CV risk. presented at the 24th Annual Congress of the European League Against Rheumatism